Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech ($MRNA). ProNAi's lead candidate is its PNT2258, which targets the BCL2 gene to slow the spread of cancer and kill the cells while minimizing side effects with its precise delivery method. For now, ProNAi is working its way through Phase II trials, and the funding round is expected to bring the company through 2016. More from FierceBiotech